Steigbigel, Roy T <br/><br/>
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.  [electronic resource] 

 -  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America  Feb 2010 
 - 605-12 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1537-6591 
<br/><br/><label>Standard No.: </label>10.1086/650002  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anti-HIV Agents--adverse effects<br/>CD4 Lymphocyte Count<br/>Double-Blind Method<br/>Drug Resistance, Viral<br/>Drug Therapy, Combination<br/>Female<br/>HIV Infections--drug therapy<br/>HIV-1--drug effects<br/>Humans<br/>Male<br/>Middle Aged<br/>Pyrrolidinones--adverse effects<br/>RNA, Viral--blood<br/>Raltegravir Potassium<br/>Viral Load